Cavosonstat: Completed Ph II enrollment

Nivalis completed enrollment of 19 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 400 mg oral N91115 twice daily for 12 weeks plus Kalydeco ivacaftor. The trial enrolle...